PARP Inhibitors Market
Market Insights on PARP Inhibitors covering sales outlook, demand forecast & up-to-date key trends
PARP Inhibitors by Drug Type (Olaparib, Niraparib, Rucaparib, Talazoparib), Indication (Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies,) & Region for 2022-2026
PARP Inhibitors Outlook – 2022-2026
[179 Pages Report] The global Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors Market is estimated to top US$ 5.51 Bn by 2022. Surging demand for advanced targeted therapy for the treatment of chronic diseases such as cancer is augmenting the growth in the market.
|
Attribute |
Details |
|
PARP Inhibitors Market Estimated Size in 2022 |
US$ 5.51 Bn |
|
PARP Inhibitors Market Projected Size in 2026 |
US$ 8.43 Bn |
|
PARP Inhibitors Market Historical CAGR (2014-2021) |
90.4% |
|
PARP Inhibitors Market Value-based CAGR (2022-2026) |
11.2% |
As per Future Market Insights (FMI), the demand in the PARP inhibitors market is expected to surpass US$ 8.43 Bn, growing at an impressive CAGR of 11.2% during the forecast period 2022-2026.
Among drug type verticals, olaparib is estimated to remain the most sought-after drug in the global market, accounting for more than 62.9% of the PARP inhibitors sales by 2022. FMI states that the PARP inhibitors are estimated to account for over 28.5% of the revenue share in the global cytotoxic toxic drugs market.
Let us know your requirement to get
100% FREE customization
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
14.56% |
|
H1, 2022 Projected |
10.84% |
|
H1, 2022 Outlook |
9.54% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 130 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 502 ↓ |
The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 130 units. A steep decline in BPS growth in H1-2022 over H1-2021 by 502 Basis Point Share (BPS) is demonstrated by the PARP inhibitors market.
The market decline observed through the drop in the BPS values is addressed by the reported haematological toxicities induced by the PARP inhibitors, and the adverse effects associated with the therapy. Moreover, PARP inhibitor therapy has been reported to pose a great financial burden on patients, thus lowering its adherence rate, and consequently, the sales adoption.
The global PARP inhibitors market is subject to drug safety guidelines, and therapeutic reimbursements, in accordance to the macro and industrial scale factors.
The key developments in the market include the identification of new target sites for the PARP inhibitor drugs, as well as their potential for application in several disease indications. The market is highly influenced by stringent policies for regulation and licensing of drugs and molecular entities used for clinical purposes.
2014-2021 PARP Inhibitors Market Outlook in Comparison to 2022-2026 Growth Forecast
PARP inhibitors are a group of pharmacological inhibitors of the enzyme, poly ADP ribose polymerase. These inhibitors block PARP enzymes, preventing healthy cells from DNA damage and assist in repairing the damaged part of DNA in cancerous cells.
According to a study by Penn Medicine Organization, use of PARP inhibitors have showcased impressive cancer patient treatment outcome, especially when combined with other therapies such as radiation and chemo.
Driven by this, PARP inhibitors has registered a robust surge in demand over the last assessment year, exhibiting growth at a staggering CAGR of 90.4% between 2014 and 2021.
Thus, growing PARP inhibitors usage for increasing cytotoxicity in cancer patients to eliminate cancer cells in BRCA-mutation cancer cell lines and inhibiting DNA damage repair when combined with chemotherapies is propelling the demand in the market. This is expected to assist the global PARP inhibitors market to total US$ 8.43 Bn by the end of 2026.
How is the Rising Burden of Cancer Creating Growth Avenues for the PARP Inhibitors Market?
Prevalence of fatal diseases such as cancer is rapidly increasing worldwide due to growing obesity and increasing smoking and alcohol consumption, resulting in propelling the demand for associated treatments.
According to a report by the World Health Organization (WHO), cancer is a leading cause of death across the world, accounting for approximately 10 million deaths in the year 2020. Out of which nearly 685,000 deaths were caused due to breast cancer.
PARP inhibitors possess the unique ability to improve progression-free survival and repair DNA damage in cells. Attributed to this, these inhibitors are extensively being used for the treatment of various types of cancers such as ovarian and breast cancer. Hence, increasing burden of cancer is estimated to create lucrative sales opportunities for cancer therapeutics such as PARP inhibitors in the coming years.
As per FMI, the sales of PARP inhibitors are estimated to total US$ 5.51 Bn by 2022, accelerating at 11.2% CAGR over the forecast period 2022-2026.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow will Increasing Number of Cancer Awareness Campaigns Elevate the PARP Inhibitors Market Growth?
With increasing prevalence and fatalities due to breast, ovarian, prostate, and other cancers, governmental and non-governmental organizations are increasingly undertaking number of public awareness campaigns regarding early cancer diagnosis and treatment.
For instance, the Ministry of Health and Family Welfare has launched a National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) to strengthen treatment infrastructure and spreads awareness regarding early diagnosis of non-communicable diseases such as cancer.
In addition to this, collaborative efforts by market players and research & academic institutes to curb cancer deaths are estimated to spur the sales of PARP inhibitors. Driven by this, the global PARP inhibitors market is expected to expand by 1.52x between 2022 and 2026.
Country-wise Analysis
What are the Factor Favoring U.S. PARP Inhibitors Growth?
“Growing Product Approvals by FDA to Bolster the Sales of Niraparib PARP Inhibitors”
The U.S. is estimated to continue dominating the North America PARP inhibitors during the forecast period 2022-2026.
As the demand for advanced cancer therapeutics such as PARP inhibitors continues to surge, leading regulatory bodies in the country are increasingly focusing on studying and granting approvals for new cancer treatment.
For instance, in 2020, the U.S. Food and Drug Administration (FDA) announced granting approval for new Niraparib PARP inhibitor monotherapy for first-line treatment for ovarian cancer. A multiplicity of such development and new product launches is anticipated to facilitate the sales of PARP inhibitors in the U.S. market.
Why is the Demand for PARP Inhibitors Surging in the India Market?
“Increasing Cases of Breast Cancer to Fuel the Demand for PARP Inhibitors”
India is forecast to emerge as a highly lucrative market for PARP inhibitors in South Asia between 2022 and 2026.
A significant rise in burden of breast cancer is being witnessed across India, creating strong demand for cancer diagnostics and treatment in the market. According to the Indian Council of Medical Research (ICMR), breast cancer is the most common type of cancer found in Indian women. In 2018, nearly 162,468 new cases and 87,090 fatalities due to breast cancer were reported across India.
As PARP inhibitors are increasingly being used in combination with other breast cancer treatments such as radiation and chemotherapies for repairing DNA damage post-exposure to ultraviolet (UV) radiation, rising prevalence of breast cancer is expected to favor the growth in the India market.
Why is the PARP Inhibitors Market in the U.K. Expanding at Rapid Pace?
“Growing Emphasis on Public Awareness Regarding Cancer to Propel the PARP Inhibitors Demand”
The U.K. is projected to account for a significant share in the Europe PARP inhibitors over the assessment period, reveals FMI.
Increasing government and non-government organizations’ emphasis on spreading public awareness regarding early diagnosis and treatment for cancer is the primary factor bolstering the sales of PARP inhibitors in the U.K. market.
For instance, Public Health England has launched a new campaign ‘Be Clear on Cancer,’ which focuses on improving early cancer diagnostics by spreading public awareness regarding cancer. In addition to this, the presence of favorable medical reimbursement policies in the U.K. is anticipated to bolster the demand for PARP inhibitors in the market.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-wise Insights
Why are Olaparib PARP Inhibitors Gaining Popularity in the Market?
“Olaparib to Remain the Most Preferred PARP Inhibitors Drug in the Market”
The olaparib segment is expected to register the fastest growth in the global PARP inhibitors market, accounting for more than 62.9% of the revenue share by the end of 2022.
Increasing product approvals and growing adoption of olaparib PARP inhibitors for the treatment of breast cancer, ovarian cancer, and pancreatic cancer is estimated to facilitate growth in the segment. Apart from this, the niraparib segment is estimated to exhibit robust growth, account for nearly 1/3rd of the PARP inhibitors sales through 2022.
Which Indication Segment will Register Robust Growth?
“Growing Adoption in Advanced First line Settings to Accelerate PARP indicator Sales”
On the basis of indication, the prostate cancer segment is anticipated to account for a significant share in the PARP indicator market through 2026, reveals FMI.
The leading factor favoring the growth in the market is growing burden of prostate cancer worldwide. According to the World Cancer Research Fund, prostate cancer is the 2nd most common type of cancer found in men and 4th most commonly occurring cancer overall.
In addition, increasing adoption of olaparib in advanced first-line settings for prostate cancer treatment is expected to spur the sales of PARP indicators in the segment.
Why are the Sales of PARP Inhibitors Rising in Retail Pharmacies Segment?
“Retail Pharmacies to Outrank Other Distribution Channels in the PARP indicator Market”
In terms of distribution channel, the global PARP indicator market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. FMI reveals that the retail pharmacies segment is forecast to account for the dominants share, creating an absolute dollar opportunity of US$ 4 Bn from 2022 to 2026.
Besides this, the online pharmacies segment is forecast to exhibit growth at a rapid CAGR through 2026. Increasing customer inclination towards using online platforms for purchasing medication and other medical accessories is projected to drive the sales of PARP indicators in the segment.
Competitive Landscape
Key companies in the global PARP indicator market are aiming at entering into collaboration, merger, acquisition, partnership and agreements with others players to develop new products for expanding their product portfilio. For instance,
- In May 2019, Clovis Oncology, Inc., American pharmaceutical company announced entering in a collaboration with two companies - Foundation Medicine Inc. and Bristol-Myers Squibb Company for initiating Phase II studies to evaluate in nivolumab combination with rucaparib in patients with endometrial ovarian cancer.
Scope of the Report
|
Attribute |
Details |
|
Forecast Period |
2022-2026 |
|
Historical Data Available for |
2014-2021 |
|
Market Analysis |
US$ Bn for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa |
|
Key Countries Covered |
US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Vietnam, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa |
|
Key Segments Covered |
Drug type, Indication, Distribution Channel, and Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, brand share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
PARP Inhibitors Market by Category
By Drug Type:
- Olaparib
- Niraparib
- Rucaparib
- Talazoparib
By Indication:
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Latin America
- South Asia
- East Asia
- Oceania
- Middle East And Africa
Frequently Asked Questions
The PARP inhibitors market is expected to surpass a valuation of US$ 5.51 Bn in 2022.
The global PARP inhibitors market grew at a 90.4% CAGR over the past assessment period 2014-2021.
The PARP inhibitors market is expected to register remarkable growth, expanding at 11.2% CAGR between 2022 and 2026.
North America will emerge as the most lucrative market for PARP inhibitors between 2022 and 2026.
South Asia PARP inhibitors market will hold a significant share over the assessment period 2022-2026.
In terms of drug type, the olaparib segment is expected to account for maximum sales in the global PARP inhibitors market through 2026.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting The Market
4. Key Inclusions
4.1. Key Regulations
4.2. Pipeline Analysis
4.3. Epidemiology for Different Cancer, By Country
5. Global PARP Inhibitors Market Demand (in Value or Size in US$ Mn) Analysis 2015-2021 and Forecast, 2022-2026
5.1. Historical Market Value (US$ Mn) Analysis, 2015-2021
5.2. Current and Future Market Value (US$ Mn) Projections, 2022-2026
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.2. Forecast Factors - Relevance & Impact
6.3. Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.3.3. Opportunity Analysis
7. Global PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026, by Drug Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2015-2021
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Type, 2022-2026
7.3.1. Niraparib
7.3.2. Olaparib
7.3.3. Rucaparib
7.3.4. Talazoparib
7.4. Market Attractiveness Analysis By Drug Type
8. Global PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026, by Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2021 - 2021
8.3.1. Ovarian Cancer
8.3.2. Breast Cancer
8.3.3. Prostate Cancer
8.3.4. Pancreatic Cancer
8.4. Market Attractiveness Analysis By Indication
9. Global PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026, by Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021 - 2021
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis By Distribution Channel
10. Global PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021
10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2021
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. South Asia
10.3.5. East Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Drug Type
11.3.3. By Indication
11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Latin America PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug Type
12.3.3. By Indication
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Europe PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. Rest of Europe
13.3.2. By Drug Type
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. South Asia PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Rest of South Asia
14.3.2. By Drug Type
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. East Asia PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug Type
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Oceania PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Drug Type
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Middle East and Africa PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026
17.3.1. By Country
17.3.1.1. Turkey
17.3.1.2. Rest of Middle East and Africa
17.3.2. By Drug Type
17.3.3. By Indication
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies (Tissue Diagnostics )
18.2. Market Concentration
18.3. Market Share Analysis of Top Players
18.4. Market Presence Analysis
18.4.1. By Regional Footprint of Players
18.4.2. Product Footprint by Players
18.4.3. Channel Footprint by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Pricing Analysis by Competition
19.3. Competition Benchmarking
19.4. Competition Deep Dive
19.4.1. Pfizer Inc.
19.4.1.1. Overview
19.4.1.2. Product Portfolio
19.4.1.3. Sales Footprint
19.4.1.4. Analyst commentary
19.4.2. AstraZeneca
19.4.2.1. Overview
19.4.2.2. Product Portfolio
19.4.2.3. Sales Footprint
19.4.2.4. Analyst commentary
19.4.3. Merck & Co. Inc.
19.4.3.1. Overview
19.4.3.2. Product Portfolio
19.4.3.3. Sales Footprint
19.4.3.4. Analyst commentary
19.4.4. GlaxoSmithKline Plc. (TESARO INC.)
19.4.4.1. Overview
19.4.4.2. Product Portfolio
19.4.4.3. Sales Footprint
19.4.4.4. Analyst commentary
19.4.5. Clovis Oncology
19.4.5.1. Overview
19.4.5.2. Product Portfolio
19.4.5.3. Sales Footprint
19.4.5.4. Analyst commentary
19.4.6. BeiGene
19.4.6.1. Overview
19.4.6.2. Product Portfolio
19.4.6.3. Sales Footprint
19.4.6.4. Analyst commentary
19.4.7. Jiangsu Hengrui Medicine Co.
19.4.7.1. Overview
19.4.7.2. Product Portfolio
19.4.7.3. Sales Footprint
19.4.7.4. Analyst commentary
19.4.8. Oncology Venture AB
19.4.8.1. Overview
19.4.8.2. Product Portfolio
19.4.8.3. Sales Footprint
19.4.8.4. Analyst commentary
20. Assumptions and Acronyms Used
21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01A: Funding by Research Areas 2021 (US$ Millions)
Table 01B: Funding by Research Areas 2021 (US$ Millions)
Table 02: Global PARP Inhibitors Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Drug Type
Table 03: Global PARP Inhibitors Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Indication
Table 04: Global PARP Inhibitors Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Distribution Channel
Table 05: Global PARP Inhibitors Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Region
Table 06: North America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country
Table 07: North America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type
Table 08: North America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication
Table 09: North America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel
Table 10: Latin America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country
Table 11: Latin America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type
Table 12: Latin America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication
Table 13: Latin America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel
Table 14: Europe PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country
Table 15: Europe PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type
Table 16: Europe PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication
Table 17: Europe PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel
Table 18: South Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country
Table 19: South Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type
Table 20: South Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication
Table 21: South Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel
Table 22: East Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country
Table 23: East Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type
Table 24: East Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication
Table 25: East Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel
Table 26: Oceania PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country
Table 27: Oceania PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type
Table 28: Oceania PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication
Table 29: Oceania PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel
Table 30: MEA PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country
Table 31: MEA PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type
Table 32: MEA PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication
Table 33: MEA PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global PARP Inhibitors Historical Market Size and Y-o-Y, 2015–2021
Figure 02: Global PARP Inhibitors Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2026
Figure 03: Global PARP Inhibitors Market Absolute $ Opportunity, 2015–2026
Figure 04: Global PARP Inhibitors Market Share Analysis (%) By Drug Type, 2022 & 2026
Figure 05: Global PARP Inhibitors Market Y-o-Y Growth (%) By Drug Type, 2022–2026
Figure 06: Global PARP Inhibitors Market Attractiveness Analysis, By Drug Type
Figure 07: Global PARP Inhibitors Market Share Analysis (%) By Indication, 2022 & 2026
Figure 08: Global PARP Inhibitors Market Y-o-Y Growth (%) By Indication, 2022–2026
Figure 09: Global PARP Inhibitors Market Attractiveness Analysis, By Indication
Figure 10: Global PARP Inhibitors Market Share Analysis (%) By Distribution Channel, 2022 & 2026
Figure 11: Global PARP Inhibitors Market Y-o-Y Growth (%) By Distribution Channel, 2022–2026
Figure 12: Global PARP Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 13: Global PARP Inhibitors Market Share Analysis (%) By Region, 2022 & 2026
Figure 14: Global PARP Inhibitors Market Y-o-Y Growth (%) By Region, 2022–2026
Figure 15: Global PARP Inhibitors Market Attractiveness Analysis, By Region
Figure 16: North America PARP Inhibitors Market Size (US$ Mn), 2015-2021
Figure 17: North America PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026
Figure 18: North America PARP Inhibitors Market Analysis by Country – 2022 & 2026
Figure 19: North America PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026
Figure 20: North America PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026
Figure 21: North America PARP Inhibitors Market Analysis by Drug Type –2022 & 2026
Figure 22: North America PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026
Figure 23: North America PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026
Figure 24: North America PARP Inhibitors Market Analysis by Indication –2022 & 2026
Figure 25: North America PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026
Figure 26: North America PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026
Figure 27: North America PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026
Figure 28: North America PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026
Figure 29: North America PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026
Figure 30: Latin America PARP Inhibitors Market Size (US$ Mn), 2015-2021
Figure 31: Latin America PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026
Figure 32: Latin America PARP Inhibitors Market Analysis by Country – 2022 & 2026
Figure 33: Latin America PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026
Figure 34: Latin America PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026
Figure 35: Latin America PARP Inhibitors Market Analysis by Drug Type –2022 & 2026
Figure 36: Latin America PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026
Figure 37: Latin America PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026
Figure 38: Latin America PARP Inhibitors Market Analysis by Indication –2022 & 2026
Figure 39: Latin America PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026
Figure 40: Latin America PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026
Figure 41: Latin America PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026
Figure 42: Latin America PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026
Figure 43: Latin America PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026
Figure 44: Europe PARP Inhibitors Market Size (US$ Mn), 2015-2021
Figure 45: Europe PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026
Figure 46: Europe PARP Inhibitors Market Analysis by Country – 2022 & 2026
Figure 47: Europe PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026
Figure 48: Europe PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026
Figure 49: Europe PARP Inhibitors Market Analysis by Drug Type –2022 & 2026
Figure 50: Europe PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026
Figure 51: Europe PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026
Figure 52: Europe PARP Inhibitors Market Analysis by Indication –2022 & 2026
Figure 53: Europe PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026
Figure 54: Europe PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026
Figure 55: Europe PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026
Figure 56: Europe PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026
Figure 57: Europe PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026
Figure 58: South Asia PARP Inhibitors Market Size (US$ Mn), 2015-2021
Figure 59: South Asia PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026
Figure 60: South Asia PARP Inhibitors Market Analysis by Country – 2022 & 2026
Figure 61: South Asia PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026
Figure 62: South Asia PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026
Figure 63: South Asia PARP Inhibitors Market Analysis by Drug Type –2022 & 2026
Figure 64: South Asia PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026
Figure 65: South Asia PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026
Figure 66: South Asia PARP Inhibitors Market Analysis by Indication –2022 & 2026
Figure 67: South Asia PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026
Figure 68: South Asia PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026
Figure 69: South Asia PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026
Figure 70: South Asia PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026
Figure 71: South Asia PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026
Figure 72: East Asia PARP Inhibitors Market Size (US$ Mn), 2015-2021
Figure 73: East Asia PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026
Figure 74: East Asia PARP Inhibitors Market Analysis by Country – 2022 & 2026
Figure 75: East Asia PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026
Figure 76: East Asia PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026
Figure 77: East Asia PARP Inhibitors Market Analysis by Drug Type –2022 & 2026
Figure 78: East Asia PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026
Figure 79: East Asia PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026
Figure 80: East Asia PARP Inhibitors Market Analysis by Indication –2022 & 2026
Figure 81: East Asia PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026
Figure 82: East Asia PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026
Figure 83: East Asia PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026
Figure 84: East Asia PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026
Figure 85: East Asia PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026
Figure 86: Oceania PARP Inhibitors Market Size (US$ Mn), 2015-2021
Figure 87: Oceania PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026
Figure 88: Oceania PARP Inhibitors Market Analysis by Country – 2022 & 2026
Figure 89: Oceania PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026
Figure 90: Oceania PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026
Figure 91: Oceania PARP Inhibitors Market Analysis by Drug Type –2022 & 2026
Figure 92: Oceania PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026
Figure 93: Oceania PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026
Figure 94: Oceania PARP Inhibitors Market Analysis by Indication –2022 & 2026
Figure 95: Oceania PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026
Figure 96: Oceania PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026
Figure 97: Oceania PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026
Figure 98: Oceania PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026
Figure 99: Oceania PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026
Figure 100: MEA PARP Inhibitors Market Size (US$ Mn), 2015-2021
Figure 101: MEA PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026
Figure 102: MEA PARP Inhibitors Market Analysis by Country – 2022 & 2026
Figure 103: MEA PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026
Figure 104: MEA PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026
Figure 105: MEA PARP Inhibitors Market Analysis by Drug Type –2022 & 2026
Figure 106: MEA PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026
Figure 107: MEA PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026
Figure 108: MEA PARP Inhibitors Market Analysis by Indication –2022 & 2026
Figure 109: MEA PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026
Figure 110: MEA PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026
Figure 111: MEA PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026
Figure 112: MEA PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026
Figure 113: MEA PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
